ADN tumoral circulante — enfermedad residual mínima (ADN-MDR)
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | BIO-CTDNA-MRD |
|---|---|
| Tipo | Biomarcador |
| Aliaces | MRD por biopsia líquidaADN tumoral circulante MRDEl DRM de la DNActctDNA-MRDenfermedad molecular residualЦиркулююча пухлинна ДНК — мінімальна залишкова хвороба (цтДНК-МЗХ) |
| Situación | reviewed 2026-04-29 | pending_clinical_signoff |
| Enfermedades | Ninguna declarada |
| Fuentes | SRC-CIVIC SRC-ESMO-CRC-2024 SRC-NCCN-COLON-2025 |
Datos sobre biomarcadores
| Tipo de biomarcador | composite_score |
|---|---|
| Medición | MétodoBiopsia líquida (plasma periférico de sangre): ensayo con tumor (por ejemplo, panel de Signatera personalizado de la EAO primaria tumoral) O panel tumor-agnóstico; FAV cuantitativa o llamada cualitativa positiva/negativa Unidadescategorical (positive | negative) and/or continuous (mean tumor molecules per mL plasma, MTM/mL) |
| Productos químicos y químicos | Ninguna declarada |
Notas
Lineage-agnostic post-treatment surveillance / risk-stratification biomarker. Two assay families: - **Tumor-informed (bespoke):** Signatera (Natera), RaDaR (NeoGenomics / Inivata) — primary tumor WES designs a patient-specific multi-locus panel; high analytic sensitivity (~0.01% VAF). - **Tumor-agnostic:** fixed-panel ctDNA assays — broader coverage of recurrent driver mutations / methylation signatures; lower specificity for low tumor burden. **CRC adjuvant (strongest evidence base):** - **GALAXY (CIRCULATE-Japan, Kotani et al. Nat Med 2023):** Stage II-IV CRC, post-curative resection, Signatera. Post-op MRD-positive patients had ~22% 18-month DFS vs ~93% MRD-negative. MRD-positive benefited substantially from adjuvant chemotherapy (vs no benefit or marginal benefit in MRD-negative). Established ctDNA-MRD as a clinically actionable risk stratifier in CRC. - **CIRCULATE-Japan ALTAIR / VEGA / CIRCULATE-US:** ongoing randomized trials of MRD-driven escalation/de-escalation. **Other lineages with growing evidence:** - Muscle-invasive bladder cancer (IMvigor010 ctDNA subgroup): MRD+ benefited from adjuvant atezolizumab; MRD- did not. - Breast (early HR+/HER2+): emerging from c-TRAK-TN...
Utilizado por
Biomarcador
BIO-CEA-CRC-MONITORING- CEA (antígeno carcinoembriónico) - Vigilancia post-tratamiento del CRCBIO-CTDNA-MRD-POST-TREATMENT- Enfermedad residual mínima basada en el ADNc (DRM) — seguimiento posterior al tratamiento